组蛋白H3K27去甲基化酶KDM6A是癌症中mTORC1信号的表观遗传守门人
该研究探讨组蛋白去甲基化酶KDM6A在肝细胞癌和胰腺癌中的功能。在30%的肝癌患者中KDM6A表达缺失,Kdm6a缺失加速小鼠肝癌和胰腺癌模型肿瘤发展并激活mTORC1信号。KDM6A通过表观遗传重塑直接激活mTORC1负调控因子如Deptor,KDM6A缺陷肿瘤对mTORC1抑制敏感。
要点
- 30%的肝癌患者存在KDM6A表达缺失,KDM6A是胃肠道肿瘤抑制因子。
- KDM6A缺失通过激活mTORC1信号加速肝癌和胰腺癌进展。
- KDM6A缺陷肿瘤对mTORC1抑制剂敏感性增加,可能指导靶向治疗。
核心结论
- KDM6A是胃肠道癌症中重要的肿瘤抑制因子,并作为mTORC1信号的表观遗传开关。
- KDM6A缺陷肿瘤患者可能从mTORC1抑制靶向治疗中获益。
研究设计与样本
- 对肝癌患者进行KDM6A遗传改变及表达分析,并构建Kdm6a缺陷的肝癌和胰腺癌基因小鼠模型。
- 进行转录组和表观遗传谱分析,以及体内外药物处理。
主要发现
- 30%的肝癌患者KDM6A表达缺失,Kdm6a缺失显著加速小鼠肝癌和胰腺癌模型肿瘤发展。
- Kdm6a缺陷肿瘤显示mTORC1信号过度激活,诱导性RNA干扰重新表达内源性Kdm6a可降低mTORC1活性并减缓肿瘤进展。
- 全基因组转录和表观遗传谱分析显示Kdm6a直接结合mTORC1关键负调控因子如Deptor,并通过表观遗传重塑激活其转录。
- 体外和体内遗传上位实验表明Deptor和mTORC1在Kdm6a依赖的肿瘤抑制中起关键作用。
- 人肿瘤中KDM6A表达与mTORC1活性相关,KDM6A缺陷肿瘤对mTORC1抑制敏感性增加。
临床怎么用
- KDM6A表达缺失可作为肝癌和胰腺癌的标志物,提示mTORC1信号激活和对mTORC1抑制剂的敏感性。
- 对于KDM6A缺陷的胃肠道肿瘤患者,可考虑mTORC1抑制靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Large-scale genome sequencing efforts of human tumours identified epigenetic modifiers as one of the most frequently mutated gene class in human cancer. However, how these mutations drive tumour development and tumour progression are largely unknown. Here, we investigated the function of the histone demethylase KDM6A in gastrointestinal cancers, such as liver cancer and pancreatic cancer. DESIGN: Genetic alterations as well as expression analyses of KDM6A were performed in patients with liver cancer. Genetic mouse models of liver and pancreatic cancer coupled with Kdm6a-deficiency were investigated, transcriptomic and epigenetic profiling was performed, and in vivo and in vitro drug treatments were conducted. RESULTS: KDM6A expression was lost in 30% of patients with liver cancer. Kdm6a deletion significantly accelerated tumour development in murine liver and pancreatic cancer models. Kdm6a-deficient tumours showed hyperactivation of mTORC1 signalling, whereas endogenous Kdm6a re-expression by inducible RNA-interference in established Kdm6a-deficient tumours diminished mTORC1 activity resulting in attenuated tumour progression. Genome-wide transcriptional and epigenetic profiling revealed direct binding of Kdm6a to crucial negative regulators of mTORC1, such as Deptor, and subsequent transcriptional activation by epigenetic remodelling. Moreover, in vitro and in vivo genetic epistasis experiments illustrated a crucial function of Deptor and mTORC1 in Kdm6a-dependent tumour suppression. Importantly, KDM6A expression in human tumours correlates with mTORC1 activity and KDM6A-deficient tumours exhibit increased sensitivity to mTORC1 inhibition. CONCLUSION: KDM6A is an important tumour suppressor in gastrointestinal cancers and acts as an epigenetic toggle for mTORC1 signalling. Patients with KDM6A-deficient tumours could benefit of targeted therapy focusing on mTORC1 inhibition.
引用
- Revia S, Seretny A, Wendler L, et al. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut. 2021. PMID: 34509979. doi:10.1136/gutjnl-2021-325405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。